Commonwealth Equity Services’s Protara Therapeutics TARA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$42K Hold
11,000
﹤0.01% 4318
2026
Q1
$57.3K Hold
11,000
﹤0.01% 4189
2025
Q4
$58.6K Buy
11,000
+1,000
+10% +$5.56K ﹤0.01% 4171
2025
Q3
$44K Buy
+10,000
New +$32.4K ﹤0.01% 4172
2025
Q2
Sell
-10,000
Closed -$43K 4350
2025
Q1
$43K Sell
10,000
-27,000
-73% -$121K ﹤0.01% 4079
2024
Q4
$195K Buy
37,000
+17,572
+90% +$56.8K ﹤0.01% 3772
2024
Q3
$36K Hold
19,428
﹤0.01% 3961
2024
Q2
$40K Buy
+19,428
New +$56.8K ﹤0.01% 3915

Other funds holding TARA

Commonwealth Equity Services's TARA Position: Q2 2026 in Review

Commonwealth Equity Services held its Protara Therapeutics (TARA) position steady in Q2 2026 at 11,000 shares worth $42K. The position accounts for ﹤0.01% of the portfolio, ranked #4318.

Commonwealth Equity Services first reported a position in TARA in Q2 2024 and has held it in 8 quarters since. The position peaked at $195K in Q4 2024. 16 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Commonwealth Equity Services held 11,000 shares of Protara Therapeutics worth $42K as of Q2 2026.
  • Commonwealth Equity Services left its Protara Therapeutics share count unchanged in Q2 2026.
  • Protara Therapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #4318 holding.
  • Commonwealth Equity Services first reported a position in Protara Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Commonwealth Equity Services's Protara Therapeutics position peaked at $195K in Q4 2024.
  • 16 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.